Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization

Fertility and Sterility

Volumn 92, Issue 5, 2009, Pages 1586-1593

  Nardo, Luciano G ^a   Gelbaya, Tarek A ^a   Wilkinson, Hannah ^a   Roberts, Stephen A ^b   Yates, Allen ^c   Pemberton, Phil ^c   Laing, Ian ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

anti M llerian hormone; Antral follicle count; controlled ovarian hyperstimulation; exogenous gonadotrophins; follicle stimulating hormone; ovarian response

Indexed keywords

BUSERELIN ACETATE; CHORIONIC GONADOTROPIN; FOLLITROPIN; MUELLERIAN INHIBITING FACTOR; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TERTIARY HEALTH CARE; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; ANTI-MULLERIAN HORMONE; CELL COUNT; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY; OVARIAN FOLLICLE; OVULATION INDUCTION; PREGNANCY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 70350572458     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.08.127     Document Type: Article

References (45)

1. Macklon N.S., Stouffer R.L., Giudice L.C., and Fauser B.C. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 27 (2006) 170-207
2. Fauser B.C., Devroey P., Yen S.S., Gosden R., Crowley Jr. W.F., Baird D.T., et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 14 (1999) 2681-2686
3. Delvigne A., and Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9 (2003) 77-96
4. Templeton A., Morris J.K., and Parslow W. Factors that affect outcome of in-vitro fertilization outcome. Lancet 348 (1996) 1402-1406
5. van Kooij R.J., Looman C.W., Habbema J.D., Dorland M., and te Velde E.R. Age-dependent decrease in embryo implantation rate after in vitro fertilization. Fertil Steril 66 (1996) 769-775
6. te Velde E.R., and Pearson P.L. The variability of female reproductive aging. Hum Reprod Update 8 (2002) 141-154
7. Broekmans F.J., Kwee J., Hendriks D.J., Mol B.W., and Lambalk C.B. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12 (2006) 685-718
8. Fauser B.C.J.M., Diedrich K., Devroey P., and on behalf of the Evian Annual Reproduction (EVAR) Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update 14 (2008) 1-14
9. Modi D., Bhartiya D., and Puri C. Developmental expression and cellular distribution of Mullerian inhibiting substance in the primate ovary. Reproduction 132 (2006) 443-453
10. Durlinger A.L.L., Gruijters M.J.G., Kramer P., Karels B., Kumar T.R., Matzuk M.M., et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142 (2001) 4891-4899
11. Durlinger A.L.L., Gruijters M.J.G., Kramer P., Karels B., Ingraham H.A., Nachtigal M.W., et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 143 (2002) 1076-1084
12. Salmon N.A., Handyside A.H., and Joyce I.M. Oocyte regulation and anti-mullerian hormone expression in granulosa cells during ovarian follicle development in mice. Dev Biol 266 (2004) 201-208
13. Weenen C., Laven J.S., von Bergh A.R., Cranfield M., Groome N.P., Visser J.A., et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10 (2004) 77-83
14. Pigny P., Merlen E., Robert Y., Cortet-Rudelli C., Decanter C., Jonard S., et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88 (2003) 5957-5962
15. Pigny P., Jonard S., Robert Y., and Dewailly D. Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 941-945
16. de Vet A., Laven J.S., de Jong F.H., Themmen A.P., and Fauser B.C. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77 (2002) 357-362
17. van Rooij I.A.J., Broekmans F.J.M., te Velde E.R., Fauser B.C.J.M., Bancsi L.F.J.M.M., de Jong F.H., et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17 (2002) 3065-3071
18. Fanchin R., Taieb J., Mendez Lozano D.H., Ducot B., Frydman R., and Bouyer J. High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 20 (2005) 923-927
19. Fleming R., Deshpande N., Traynor I., and Yates R.W. Dynamics of FSH-induced follicular growth in subfertile women: a relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 21 (2006) 1436-1441
20. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., and Shelden R.M. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77 (2002) 468-471
21. Hazout A., Bouchard P., Seifer D.B., Aussage P., Junca A.M., and Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82 (2004) 1323-1329
22. Muttukrishna S., Suharjono H., McGarrigle H., and Sathanandan M. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?. BJOG 111 (2004) 1248-1253
23. Penarrubia J., Fabregues F., Manau D., Creus M., Casals G., Casamitjana R., et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 20 (2005) 915-922
24. Tremellen K.P., Kolo M., Gilmore A., and Lekamge D.N. Anti-müllerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol 45 (2005) 20-24
25. Nelson S.M., Yates R.W., and Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 22 (2007) 2414-2421
26. Broer S.L., Mol B.W., Hendricks D., and Broekmans F.J. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril (2008) [March 03, Epub ahead of print]
27. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
28. Faddy M.J. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 163 (2000) 43-48
29. Kodama H., Fukuda J., Karube H., Matsui T., Shimizu Y., and Tanaka T. High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Hum Reprod 10 (1995) 1962-1967
30. Engmann L., Maconochie N., Sladkevicius P., Bekir J., Campbell S., and Tan S.L. The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 14 (1999) 167-171
31. Bellver J., Muñoz E.A., Ballesteros A., Soares S.R., Bosch E., Simón C., et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 18 (2003) 2283-2288
32. Eldar-Geva T., Margalioth E.J., Gal M., Ben-Chetrit A., Algur N., Zylber-Haran E., et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 20 (2005) 1814-1819
33. van Rooij I.A., Broekmans F.J., Scheffer G.J., Looman C.W., Habbema J.D., de Jong F.H., et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83 (2005) 979-987
34. Ficicioglu C., Kutlu T., Baglam E., and Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 85 (2006) 592-596
35. Nakhuda G.S., Chu M.C., Wang J.G., Sauer M.V., and Lobo R.A. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 85 (2006) 1541-1543
36. La Marca A., Giulini S., Tirelli A., Bertucci E., Marsella T., Xella S., et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22 (2007) 766-771
37. La Marca A., Stabile G., Artenisio A.C., and Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21 (2006) 3103-3107
38. Hehenkamp W.J., Looman C.W., Themmen A.P., de Jong F.H., Te Velde E.R., and Broekmans F.J. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 91 (2006) 4057-4063
39. Wunder D.M., Bersinger N.A., Yared M., Kretschmer R., and Birkhäuser M.H. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 89 (2008) 927-933
40. Fréour T., Mirallié S., Bach-Ngohou K., Denis M., Barrière P., and Masson D. Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 375 (2007) 162-164
41. Sadraie S.H., Saito H., Kaneko T., Saito T., and Hiroi M. Effects of aging on ovarian fecundity in terms of the incidence of apoptotic granulosa cells. J Assist Reprod Genet 17 (2000) 168-173
42. Ebner T., Sommergruber M., Moser M., Shebl O., Schreier-Lechner E., and Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 21 (2006) 2022-2026
43. Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., and Tapanainen J.S. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 20 (2005) 1820-1826
44. Klinkert E.R., Broekmans F.J., Looman C.W., Habbema J.D., and te Velde E.R. The antral follicle count is a better marker than basal follicle-stimulating hormone for the selection of older patients with acceptable pregnancy prospects after in vitro fertilization. Fertil Steril 83 (2005) 811-814
45. Al-Inany H.G., Abou-Setta A.M., and Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 3 (2006) CD001750